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The use of trained dogs for the detection of volatile biomarkers in biological 
samples has great potential to be used for non-invasive diagnosis and monitoring 
of several diseases such as cancer. It offers early, highly accurate detection with fast 
response times, non-invasive to patients and allows for repeated sampling. The 
aforementioned methods are useful as a portable technology to increase detection, 
screening, and monitoring coverage in populations at risk. In this sense, Cervical 
Cancer (CC) has become a public health concern of alarming proportions in many 
developing countries, particularly in low-income sectors and marginalized regions 
due to different factors that limit the coverage of screening methods and the accep-
tance rates of women attending their routine gynecological examination. As such, 
early detection is a crucial medical factor in improving not only their population’s 
quality of life but also its life expectancy. For the above, the great odor detection 
threshold exhibited by dogs is not unheard of and represents a potential opportu-
nity to develop an affordable, accessible, and non-invasive method for detection of 
CC with high sensibility and specificity values.
Keywords: cervical cancer, dog detection, volatile organic compounds
1. Introduction
There is significant potential to reduce the suffering from cancer and to alleviate 
the economic burden to individuals, families, and societies. It is known that preven-
tion campaigns and early detection interventions can avert cancer cases and deaths 
in high- and low-resource settings. Although many countries and communities have 
limited resources for screening, several common cancers among females such as 
Cervical Cancer (CC) have known means of prevention and/or early detection that 
can be applied in resource-appropriate settings [1].
Cervical cancer is one of the female reproductive system cancers, and it is a fun-
damental cause of cancer morbidity and mortality worldwide. This complex disease 
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is relatively common with estimates of more than half a million new cases in 2018, 
and it accounts for 13% of all cancers in women in developed regions [2, 3]. The 
highest incidence rates (greater than 20 per 100,000 women) are found in Eastern, 
Western, and Southern Africa, South-Central Asia, South America, Melanesia, and 
Central Africa [3].
There are different tools to achieve CC elimination. The World Health 
Organization (WHO) has identified three critical targets to the elimination of this 
cancer type mainly in the increased coverage of: 1) Human Papillomavirus (HPV) 
vaccination, 2) Screening for premalignant disease with an HPV test, and appropri-
ate management of women who screen positive, and 3) Reducing mortality from 
cervical cancer by providing appropriate treatment [4].
In recent years HPV vaccination in high-income countries has resulted in 
dramatic decreases in HPV infection and associated cervical disease as a primary 
prevention strategy for CC. Unfortunately, this has not happened in low- and 
middle-income countries where the access to the vaccination is limited mainly by 
the high cost, and therefore most women and girls at most risk cannot be protected. 
As a secondary prevention strategy, progress has been made in cervical precancer 
screening and treatment, but we must accelerate this momentum to reduce inci-
dence and mortality worldwide to the meager rates found in wealthier countries [5]. 
In this sense, given that the access of the different CC prevention strategies is not 
equitable between countries or even inside of each country, due to the differences in 
infrastructure and access to health care systems so marked that we could find, it is 
necessary to search new tools and screening strategies. One of these strategies could 
be constituted by the markers present in the scent of CC cells.
The analysis of odors or volatile biomarkers emitted by cancer cells is of great 
value in the development of new diagnostic tests as low-risk methods for the early 
cancer diagnosis and a regular screening for all women, including the marginal-
ized or disadvantaged. These volatile signatures are present in different biofluids 
and show a physiological status. In cancer, the analysis of these molecules has been 
demonstrated as a rapid and noninvasive alternative by analytical and biological 
ways as the use of trained dogs for the detection of several cancers.
Dogs can smell a trace of volatile odorous molecules or biomarkers (parts per 
trillions) emitted in different biofluids [6]. They have an extraordinary ability to 
recognizing odorous biochemical signature expressed only in ailing individuals but 
not in healthy individuals, in much earlier and better ways and with an accuracy 
comparable or superior to readily available sophisticated diagnostic instruments 
of the present time [6, 7]. The extraordinary canine sense of smell could avoid the 
unnecessary painful procedures on patients and minimize the time and expenditure 
on the diagnosis made through the biopsy and other tests having compromised 
sensitivity, specificity and predictive values resulting into inadequate accuracy. In 
CC, it could be an effective promissory weapon in fighting this disease and saving 
women’s lives [7].
2.  Cervical cancer as an important public health concern related to a 
virus infection
Among of the gynecological cancer types, CC must be the most detectable 
cancer due to access to the anatomical target. Unfortunately, this cancer type is the 
fourth most frequent cancer in the female population worldwide. More than 85% 
of cases occur in developing countries in which this malignancy is a public health 
concern due to its high mortality rates, provoked at least by late detection and lack 
of coverage for screening procedures [8]. Prior to the appearance of CC, women 
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develop a precancer period that spans approximately two decades. During this 
extensive period, cervical epithelium cells present morphological and molecular 
changes that could not be typical of a healthy state neither of cancer; they are 
in transition state, as in the “limbo”. Thus, these abnormal or precancer cells are 
known as squamous intraepithelial lesions (SIL) classified as low grade (LSIL) if 
they only affect the first third of the cervical epithelium, or high grade (HSIL) if 
they affect more than 50% of cervical epithelium layer [9].
Like other cancers, CC is a multifactorial disease, although there are different 
risk factors that could be controlled to prevent the development and progression of 
precursor lesions to invasive cancer. Among these risk factors are the onset of active 
sexual during the teen period, multiple sexual partners, overuse and uncontrolled 
of hormonal contraceptives, drug abuse, inadequate and overuse of antibiotic 
regimens, lack of protection during sexual intercourse and absence of routine 
gynecological inspections, among others; however, the main etiological factor 
associated with this type of cancer is the persistent HPV infection considered as 
sexually transmitted infection [10, 11].
The HPV is an infectious agent that is transmitted through sexual contact and 
affects the anus-genital and oropharyngeal tracts. This involves the transmission 
of one or more viral genotypes that infect the epithelia, which ones are classified as 
low risk (LR-HPV) and high risk (HR-HPV) according to their carcinogenic poten-
tial. Persistent infection by any of the HR-HPV genotypes is the cause of the vast 
majority of SIL [12]. It should be noted that the process of cellular transformation 
of normal cells to precancerous cells and invasive carcinoma involves a long period 
of time, as already mentioned, which makes the prevention of this neoplasm 100% 
feasible through the SIL screening.
3. CC and SIL screening
There are two approaches for CC screening and its precursor lesions. The first 
one is a cellular level approach (micro) involving cervical Pap smear cytology, and 
the second one is a tissue level approach (macro) through visual inspection iodine 
Lugol (VILI) or visual acid acetic inspection (VIA) and colposcopy [9].
A conventional Pap smear, which involves removing epithelial cells from the 
surface of the cervix with a brush (cytobrush or cervix brush) or spatula and then 
transferring them to a glass slide where they are prepared with Pap stain to be 
examined by a cytotechnologist or pathologist and discriminate between normal 
and abnormal cells by using conventional light microscopy. Colposcopy involves the 
inspection of the cervical tissue through a colposcope which allows magnification of 
the cervix up to 40X. The solutions already mentioned can be used to reveal changes 
in maturation, differentiation or abnormal epithelium vasculature that indicate the 
presence of SIL or CC [13]. It is worth mentioning that in the last years HPV testing 
is replacing cytology as the preferred cervical screening method; however, the 
interpretation of the HPV testing must be carried out with reservation [14].
HPV infection is one of the most prevalent sexually transmitted infections, 
generally symptomatic, with a worldwide prevalence in women with normal 
cytology of 11.4% and 99% in CC cases. Nevertheless, HPV infection is a necessary 
but not a sufficient cause of CC. Therefore, the positivity rate of HPV test is higher 
than cytology and that most positive test results do not indicate a high absolute risk 
of CC [15, 16]. These results could interpret as “false positive” CC screening results 
according to the use of this test as a screening tool for this cancer. This does not 
mean that HPV is not present; instead, we are referring to the detection of only an 
HPV infection that is not destined to cause CC [14].
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4. Why is there CC?
As we know, CC is a preventable disease, and it has been shown that cervical 
cytology or Pap smear has been decreased the mortality rate of CC in developed 
countries. Unfortunately, this has not happened in low- and middle-income 
countries in which almost 9 out of 10 cervical cancer deaths occur, continuing as a 
priority health problem due to different social and technical factors involved [2].
CC screening program needs to be sufficiently accurate and acceptable for the 
target population by way of allowing the early detection of the disease and the 
triage of screen-positive women who requires colposcopy or treatment. To ensure 
the effectiveness of the screening, it is necessary a coverage rate of at least 80% of 
the population [2, 17]. Nevertheless, average Pap smear coverage is approximately 
18.5% in developing countries, 63% in developed countries and 39.6% across the 
globe. These percentages could differ in each country but are clear that in any case, 
the coverage of Pap smear needs to be improved [18].
Pap smear and colposcopy are highly invasive methodologies since they require 
the introduction of a vaginal speculum to gain access to the cervix, thereby compro-
mising the intimacy of the woman. Most of the screened women suffer shame, pain, 
inconvenience, or nervousness during the screening procedure, or can experience 
lower abdominal pain or vaginal bleeding in the days following the test. Women 
have reported a lack of information before or during gynecological inspections, and 
sometimes, they have referred a disrespectful attitude and a lack of engagement 
from the medical staff, resulting on women delaying their gynecological inspection 
or avoiding it altogether [19].
There are other social aspects interfering with the coverage of Pap screening in 
the risk population. Inadequate knowledge about the purpose and benefits of Pap 
smears, the fact that many screened and non-screened women do not know the 
meaning of an abnormal result. The fear and anxiety of having cervical abnormali-
ties which affect the future decision to have a Pap test, social and health inequalities 
between women as a lack of health insurance, faults of organization in health-care 
programs involving in the appointment scheduling and the long waiting times to get 
a result, religious beliefs, taboo, fear of stigmatization, etc. [20, 21].
There are several technical limitations of the Pap smear screening as the speci-
men collection that imply collection and processing time, the procedure as the 
smear is taken, the quality of the samples, processing standards, lack of training 
of cytotechnologists for the accurate interpretation of results, the loss of con-
centration and fatigue that suffer by a repetitive task (up to 50 times a day) of 
visualization of slides. This provokes the rates of false-negative that can conduce to 
an increase in the cost CC screening and bad prognosis for the patients, as well as, 
the false- positive results that could cause psychological stress, overdiagnosis and 
 overtreatment [9, 13].
5. OMIC era in the diagnosis of the diseases: volatilome and volatolome
To find alternative tools in cancer diagnosis in an earlier and more precise 
manner, researchers have explored the use of Metabolomics, specifically the volatile 
organic compounds (VOC) to detect these complex diseases.
VOC are carbon-based chemicals, volatile at room temperature and pressure, 
and source of most odors. Being produced during metabolic processes in millions 
of cells simultaneously, thus they are potentially releasing in an extracellular way 
on a detectable scale and may be emitted from different areas of the body prone 
to odor production e.g., scalp, axillae, feet, groin, oral cavity. These also can be 
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excreted through different biofluids as saliva, breath, blood, sputum, feces, sweat, 
urine and may serve as ideal clinical biomarkers for several pathophysiological 
processes. The entire set of VOC produced by an organism is called Volatilome, and 
their accumulation inside and outside of the body reflects a unique metabolic state 
in an organism [6, 22, 23]. This knowledge is too old; the ancient Greek and Chinese 
human noses were the first to identify and describe the diagnostic potential of 
VOC in the diseases through the smell of different biological samples such as urine 
and sputum. Based on this ancestral knowledge, we know the VOC potential in the 
medical field, and ever since, our sense of smell has been used in medical practice as 
a more precise and less invasive diagnostic tool for the detection of several diseases 
[24]. Among the several diseases characterized by a specific odor are diabetes 
(rotten apple odor in the breath), scurvy (putrid body odor), cholera (rice water), 
trimethylaminuria (rotten fish-like odor in the breath, vaginal fluid, sweat and 
urine), phenylketonuria (musty odor), cystic fibrosis (chloride), or typhoid fever 
(baked bread body odor), etc. [25, 26].
Interestingly, in the last few decades, the diagnosis potential of VOC has focused 
on the search of the volatile profiles of many cancers in all the biofluids as the 
urine, feces, exhaled breath, and saliva of patients. The rationale for this is that 
cancer cells have different metabolic or biochemical requirements in comparison 
from normal cells, due to the genetic alterations that acquire and that allow them 
to proliferate outside the context of normal tissue development [27]. Therefore, 
the metabolic and bioenergetic alterations presented by tumor cells lead to a VOC 
profile different from that of healthy cells. These VOC profiles are useful for the 
diagnostic of cancer, predict patient response towards chemotherapies or treatment 
and monitor disease recurrences [28].
For example, the lack of sensitive and specific biomarkers for the early detection 
of prostate cancer led a Portuguese research group to investigate the performance 
of VOC present in the urine of patients as potential markers for this cancer in a 
metabolomic approach based on the analytical tool, the Gas Chromatography–Mass 
Spectrometry (GC–MS), finding a urinary profile of VOC different from that of 
cancer-free subjects with 78% sensitivity, 94% specificity and 86% accuracy [29].
A research group in the UK assessed the utility of VOC as feces biomarkers for 
colorectal neoplasia by headspace extraction followed by GC–MS. This group found 
that Propan-2-ol was the volatile organic compound most strongly associated with 
cancer, and 3-methylbutanoic acid or DL-menthol was the only volatile organic 
compound negatively associated with cancer. These VOC showed a diagnostic 
ability of sensitivity 87.9% and specificity 84.6% in the identification of colorectal 
adenocarcinoma [30].
Another example was research in which the gastric cancer was correlated with 
specific VOC biomarkers in the exhaled breath of a South American population. 
The exhaled VOC were analyzed by GC–MS and by a chemical gas sensor based on 
gold nanoparticles functionalized with octadecylamine ligands. Six VOC showed 
statistically significant differences between the cancer patients and the controls 
group (e.g., hexadecane and octadecane in the gastric cancer group, while eicosane 
and 1-cyclohexyl-2-(cyclohexylmethyl) pentane were identified as biomarkers in 
the control group). The sensor data responses to the breath samples yielded 97% 
accuracy, 100% sensitivity and 93% specificity [31].
Recently in Japan, the salivary metabolomic profile of oral squamous cell 
carcinoma was established through VOC analysis as potential biomarkers for the 
diagnosis of oral cancer through a method combining thin-film microextraction 
based on a ZSM 5/polydimethylsiloxane hybrid film coupled with GC–MS in saliva 
samples of oral cancer patients and healthy controls in which eighty kinds of vola-
tile metabolites that were detected and identified and were classified as alcohols, 
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ketones, hydrocarbons, aldehydes, organic acids, esters, phenols, etc. Among them, 
twelve COV were selected as potential oral cancer biomarkers for their use as non-
invasive tools for the possible diagnosis of this cancer [32].
The above were just some examples of the vast literature that currently exists 
on the analysis of VOC for the diagnosis of different cancers through non-invasive 
samples and analytical methods.
6. Analytical chemistry (electronic noses) in VOC detection
As it was mentioned already, the analysis of VOC as cancer biomarkers in diverse 
biofluids is desirable because it allows a repeated sampling and a non-invasive and 
quick analysis. In this sense, there is great potential for the development and clinical 
application of VOC analysis in the diagnosis and monitoring of cancer [33].
The number of studies demonstrating the potential of VOC in cancer diagnosis 
has increased in the last decades due to analytical chemistry advancements that 
have made possible the quantitative analysis and comparison of VOC of cellular 
origin [6, 23].
From the several analytical techniques that exist, the GC–MS, Selected Ion Flow 
Tube Mass Spectrometry (SIFT-MS), Proton Transfer Reaction Mass Spectrometry 
(PTR-MS), Proton Transfer Reaction Time of Flight (PTR-ToF) and Ion Mobility 
Spectrometry (IMS) have been the most used to separate and identify VOC. These 
are sophisticated and valuables stationary analytical chemical instruments for the 
discovery of biological scents [34].
However, despite the low detection limits and high sensitivity offered by these 
methodologies, they present certain limitations that have prevented their routine 
application as screening methods. These require high levels of technical expertise 
and lengthy instrument run times (tens-of-minutes to hours) for detailed chemi-
cal analysis. Most of them, exceptionally high-resolution mass spectrometers, are 
extremely expensive and require expert maintenance. Furthermore, data interpreta-
tion, especially for non-targeted analyzes, may initially take many hours per sample 
until sufficient statistical results are accumulated to develop a targeted approach. 
Finally, they require infrastructure and trained personnel for their  operation [35].
7. Dogs (biological noses) as clinical tools in cancer detection
Dogs have excellent odor detection capabilities in a vast range of fields. Their 
olfaction is a fundamental sense that let them perceive and comprehend the world 
around them. Humans have harnessed the canine sense of smell for the detection of 
different targets as an orthodox manner, such as explosives, land mines, narcotics, 
missing persons (forensic area), and invasive or endangered species [34, 36]. Right 
now, in this pandemic situation worldwide, dogs have been trained for COVID-19 
early detection [37]. The question arises, why not use the canine olfactory for cancer 
detection?, nevertheless in the last decades, the use of canine olfaction as a diagnos-
tic tool for identifying preclinical disease, especially cancer in biological samples 
has increased [34, 38].
Nowadays, there are a considerable number of publications using trained dogs 
to sort biological samples for follow-up and future diagnostics [31]. Several authors 
have published research suggesting that dogs can sort dozens of samples, includ-
ing blind replicates and known control samples in a few minutes and may be able 
to detect lung, breast, prostate, ovarian, and melanoma cancers by smelling skin 
lesions, urine, exhaled breath, and surgically extracted tumors [35, 39].
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The first report of dogs’ potential to detect cancer was published in 1989 in the 
UK when a pet dog spontaneously detected its owner’s melanoma, saving her life. 
After it, several additional cases of spontaneous cancer detection by dogs were 
reported, this caught the attention of the scientific community, and canine olfac-
tion began to be used in the search for increasingly sensitive and specific diagnostic 
techniques for diseases as cancer where mass screening and early diagnosis could be 
improved [40].
In pilot work, a research group demonstrated the validity of using dogs as a 
biological system to examine exhaled breath in the diagnostic identification of 
lung and breast cancers. Its results showed an overall 99% sensitivity and specific-
ity for canine scent detection among lung cancer patients and controls compared 
to biopsy-confirmed conventional diagnosis and 88% of sensitivity and 98% of 
specificity among breast cancer patients and controls [41].
Another research group in France, trained a Belgian Malinois shepherd by the 
clicker training method for prostate cancer detection on human urine samples. 
Its results showed that dogs could be trained to detect prostate cancer by smelling 
urine with a significant success rate (91% of sensitivity and specificity) suggest-
ing that prostate cancer gives an odor signature to urine and it could be used as a 
potential screening tool [42].
In another research study, the ability of dogs to detect ovarian cancer from 
plasma samples was evaluated and how the odor associated to this cancer is affected 
by the treatment to reduce tumor burden, including surgery and five courses of 
chemotherapy. The dogs showed high sensitivity (97%) and specificity (99%) for 
the detection of ovarian cancer patients’ plasma and indicated positive samples 
from patients who had recurrences. For the above, the dogs offer an outstanding 
assessment of ovarian cancer prognosis based on the specific odor in the blood 
which could enhance primary diagnosis and enable earlier relapse diagnosis and 
consequently an increase in patient’s survival [43].
At present, Medical Detection Dogs in the UK an organization that is at the 
forefront of innovative research in the dogs’ ability to detect the smell of human 
diseases and save lives. This organization focuses on detecting the VOCs associated 
with prostate cancer and colorectal cancer using trained dogs as a non-invasive 
method that can detect cancer at an early stage could both increase uptake of the 
screening and improve health outcomes [44].
Another current medical innovation research program is KDOG sustained by 
French Institute Curie (Paris) who is elaborating a simple, non-invasive, and cost-
effective breast cancer screening method, based on canine detection. This method 
is contactless between the animal and the patient and the dogs’ success rate in 
cancer detection that has been reported was about 100% [45].
8. Canine detection of cervical cancer
Issues concerning CC detection make it necessary searching for alternatives that 
help to increase the early screening coverage with greater percentages of sensitiv-
ity and specificity in screening and diagnostic tests. The introduction of methods 
capable of detecting virtually invisible -a single molecule among a billion or tril-
lions of compounds- changes in the cell through the analysis of cells “odor” have 
much in their favor in practical applications. In this way, the key could rely upon 
the poorly explored field of the metabolomics of the cervicovaginal epithelium. 
Biotechnological and analytical systems such as dogs and analytics as GC–MS may 
be alternatives to current tests which leaves us with two good panoramas: 1) a labo-
ratory analytical test; 2) a biotechnological field test; both of which use a “volatile 
Canine Genetics, Health and Medicine
8
biopsy”, basically a scent sample, obtained without penetrating the human body at 
all. Our work team has proposed a device specifically made for this purpose [46, 47].
This device that our research group has developed is a gadget worn by the 
patient for a defined period, after which is simply stored in a container -provided 
by us- and mailed to the recipient, avoiding the stress of queuing in a hospital. Our 
device quickly collects in an unorthodox manner the VOC of the genitourinary tract 
allowing us, to use analytical devices GC–MS system for sample examination, with 
the surplus of being simple to dispose of after analysis is done. Each sample being 
scanned in one hour. Afterwards, the metabolic profile is reviewed by an expert to 
determine if there are any volatile biomarkers associated with the sample.
In this unorthodox scenario (for some people), this device is scanned by a 
trainer-dog binomial test carried out in seconds. In such an analysis, our gadget 
eliminates the shock some people could have by watching a dog “deciding their 
fate”. Our results in both scenarios show that a sample’s VOC profile result by the 
analytic test and detected by a trained dog, discriminates between cancerous and 
non-cancerous samples with more than a 90% sensitivity and specificity. These data 
are correlated afterwards to histopathological observation as the gold standard, 
suggesting that the device has a great value proposition [46, 47].
These proposals represent the ideal diagnostic tests for screening CC because 
they are non-invasive, low cost, accurate and partially portable, therefore meeting 
the requirements for a good screening test according to WHO. This established that 
a screening test must be sufficiently accurate to detect the condition earlier than in 
the absence of screening [48].
Recently another research group in Japan trained a dog to distinguish urine 
samples from cervical cancer patients from those of the controls, showing that 
cancer detection by dog sniffing can be a non-invasive, cost-effective screening 
technique for CC [49]. This report supports our proposal that the canine nose can 
be used and developed for CC detection.
The use of screening dogs is a real issue, for instance, they play vital roles 
helping in natural disasters or detecting drug or weapons trafficking as we have 
mentioned before; in the case of GC–MS itself is used again in the detection of 
drug trafficking, anti-doping or as a standard test in food products; then, why then 
should not they be used in the health-care industry? An example is the exhalomic 
test “Hearts Breath Test for Grade 3 Heart Transplant Rejection detection”. Dr. 
Phillips et al. at Menssana Research Inc. in New Jersey USA developed this FDA 
approved test. This test detected a specific metabolomic profile and had opened a 
vast opportunity in the marketing of metabolomic or volatolomic tests [50].
9. A big challenge and an alternative
Pap test was not specifically developed to detect neither human cervical lesions 
nor HPV infection [44]. Moreover, it has not been subjected to a rigorous analysis 
regarding its sensitivity and specificity; however, it is the accepted test for detect-
ing cytomorphological changes in the cervicovaginal epithelium but not for HPV. 
Epidemiological studies show that HPV detection does not necessarily indicate 
cancer, so it is considered necessary but not enough for CC development [51].
On the other hand, the CC research has served to define that prior to this type of 
invasive lesions, there are precursor or pre-invasive lesions as SIL, thanks to epide-
miological studies, it has been determined that less than 10% of women infected 
with HPV will develop CC [52]. So far, it is unknown what factors are indispens-
able for the progression of these lesions causing “headaches” among oncologist and 
gynecologists alike, for nobody knows which SIL will progress to a more aggressive 
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lesion. Many questions result in no concrete answer. Given these facts, the new 
OMICs area opens the opportunity for the early detection of pre-invasive lesions. 
Combining analytical and biotechnological procedures as aforementioned will 
permit the basis for new portable nanosystems.
In summary, our proposals are affordable and accessible for any women and 
could be an important weapon in this war against CC as a preventive measure 
deployed by health services, all this granting the public and government depart-
ments accept them.
10. Conclusions
Early detection saves lives. Therefore, it is necessary to implement new and 
alternative technologies that allow the development of accessible diagnostic meth-
ods that cover at least some of the limitations presented by conventional screening 
tests for the detection of diseases such as cancer, especially Cervical Cancer.
The canine detection of odors or volatile profiles emitted by cancer cells is a 
portable, highly sensitive and specific tool which could be used as a screening 
alternative (as fast track) in marginalized or areas of difficult access (even in the 
urban regions) to increase coverage in high-risk populations. Additionally, the use 
of a trained dog for screening could facilite prevention campaigns, saving money, 
time, labor, and lives due to an early diagnosis.
The CC and its precursor lesions detection is a priority health concern in differ-
ent countries, therefore having an analytical alternative (GC–MS) and a biological 
alternative (canine smell) for screening could be a great support technique for 
conventional methods offering a non-invasive, fast, and accurate detection that can 
be carried out repeatedly and that would also be useful for monitoring the disease.
Applications for these tools extend to providing much needed medical attention 
for women from cultural backgrounds imposing several prohibitions, deep-rooted 
cultural taboos, religious beliefs, shame, or lack of health coverages. We thought 
that a “with a little help” to current methods by using improved, non-expensive 
and innovative procedures will conduct to accurate and timely diagnostics for this 
cancer type. Unfortunately, for both analytical and bio-detection methods, there is 
no consensus in the methodologies used or in the results obtained, thus this is a call 
to join forces with the scientific and social communities (research groups) for the 
replication of the studies that lead to the future implementation of these method-
ologies for clinical diagnosis.
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